Lynx Capital 德石资本
Healthcare Focus, Global Resource, China Angle
Who We Are
Lynx Capital is a healthcare and life science -focused fund, investing in innovative companies in western countries in both therapeutics and medical technology areas, with a potential to collaborate with Chinese companies to explore the China market. With the extensive expertise and experience in both China and the States, and deep understanding of healthcare and business, Lynx Capital believes that it is well positioned to help with such collaboration.
Basel, Switzerland / Kuopio, Finland – March 30th 2023. Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs.
Edinburgh, Mar 8, 2023 -- Calcivis, dental imaging technology company, is setting its sights on US growth having secured pre-market approval (PMA) from the US Food and Drug Administration (FDA). As the first Scottish medical device to secure the coveted accreditation, the Calcivis Imaging System aims to revolutionise the dental sector by enabling the move to a more preventive treatment model.
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 28, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Shanghai-based Lynx Financial served as Aurealis' exclusive financial advisor in this transaction.